Entest Biomedical, Inc.'s ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous Side Effects
9/6/2012 9:42:53 AM
More...
|
Entest Biomedical, Inc. Sees Entry into $300 Million Veterinary Cancer Care Market Through Veterinary Hospital Acquisitions
9/4/2012 9:34:35 AM
More...
|
Entest Biomedical, Inc. Excited With Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine Osteoarthritis
3/21/2012 8:48:08 AM
More...
|
Entest Biomedical, Inc. Declares Dividend of Preferred Stock
2/13/2012 5:57:03 AM
More...
|
Entest Biomedical, Inc. Launches Investor Relations Campaign
12/7/2011 6:42:36 AM
More...
|
Entest Biomedical, Inc. Enters into Purchase Agreement With Oregon-Based Veterinary Hospital
11/8/2011 8:44:51 AM
More...
|
Entest Biomedical, Inc. Signs Agreement With RenovoCyte and MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) for Pilot Study Using Universal Donor Stem Cells in Treatment of Dog Osteoarthritis
10/24/2011 9:54:00 AM
More...
|
Entest Biomedical, Inc. Announces Promising Results From ImenVax(TM) Canine Cancer Vaccine Safety Study
7/28/2011 6:26:34 AM
More...
|
Entest Biomedical, Inc. Unit Prepares to Enter the $58 Billion U.S. Pet Products Market by Establishing Online Veterinary Products Store
7/26/2011 9:07:55 AM
More...
|
Entest Biomedical, Inc. Signs Letter of Intent to Acquire Assets of Oregon-Based Veterinary Clinic
7/25/2011 8:29:52 AM
More...
|
|